Education
About Us
Working with TipRanks
Follow Us
VFMF - ETF AI Analysis
Top Page
Vanguard U.S. Multifactor ETF (VFMF)
Rating:71Outperform
Price Target:―
Positive Factors
Broad Sector Diversification
The fund spreads its investments across many sectors, which can help reduce the impact if any one industry struggles.
Generally Strong Recent Performance
The ETF has shown solid gains over the past three months and year to date, indicating positive recent momentum.
Low Expense Ratio
The fund’s relatively low annual fee means more of the returns stay in investors’ pockets compared with many actively managed strategies.
Negative Factors
Heavy U.S. Concentration
Almost all of the ETF’s assets are invested in U.S. companies, offering very little geographic diversification.
Tilt Toward Financials and Health Care
Large weights in financial and health care stocks mean the fund could be more affected if these sectors face a downturn.
Mixed Performance Among Top Holdings
While several leading positions have performed strongly, a few key health care names have been weak, which can drag on overall returns.
VFMF vs. SPDR S&P 500 ETF (SPY)
AUM551.94M
RegionNorth America
Expense Ratio0.18%
Beta0.91
IssuerVanguard
Inception DateFeb 13, 2018
Dividend Yield1.43%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume27,704
30 Day Avg. Volume19,765
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
181.31Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering577
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
VFMF Summary
Vanguard U.S. Multifactor ETF (VFMF) is a fund that invests in a wide range of U.S. companies across many sectors, including financials, health care, and technology. It doesn’t track a single index, but instead follows a “multifactor” theme, choosing stocks based on traits like value, recent performance, and business quality. Well-known holdings include AbbVie and Merck. Someone might invest in VFMF for broad diversification and the potential for long-term growth from many parts of the U.S. market. A key risk is that its stock prices can go up and down with the overall market.
How much will it cost me?The Vanguard U.S. Multifactor ETF (VFMF) has an expense ratio of 0.18%, meaning you’ll pay $1.80 per year for every $1,000 invested. This is slightly higher than the average for passively managed ETFs because it uses a multifactor strategy to select stocks, which requires more active management. However, it’s still relatively low compared to actively managed funds.
What would affect this ETF?The Vanguard U.S. Multifactor ETF (VFMF) could benefit from positive trends in the U.S. economy, such as strong consumer spending and technological innovation, which align with its exposure to sectors like Consumer Cyclical and Technology. However, it may face challenges from rising interest rates, which could impact its Financial sector holdings, and economic slowdowns that might affect cyclical industries like Industrials and Energy. Regulatory changes in healthcare or financial services could also influence the performance of its top holdings, such as Gilead Sciences and Wells Fargo.
VFMF Top 10 Holdings
VFMF’s story right now is a tug-of-war between surging chip names and more cautious health care and defensive plays. Lam Research and Micron are doing the heavy lifting, riding strong momentum in AI and semiconductors and giving the fund a clear tech undercurrent despite its multifactor label. On the flip side, AbbVie and Regeneron have been more mixed to lagging, keeping health care from fully pulling its weight, while Altria’s steady but uninspiring path adds a defensive, slow-and-steady note. Overall, it’s a U.S.-only portfolio with leadership tilted toward tech strength over pharma softness.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Newmont Mining | 1.12% | $6.24M | $137.28B | 164.79% | 81 Outperform | |
| Gilead Sciences | 1.02% | $5.69M | $192.28B | 47.52% | 78 Outperform | |
| Altria Group | 0.97% | $5.42M | $112.89B | 27.49% | 64 Neutral | |
| HCA Healthcare | 0.97% | $5.41M | $120.82B | 70.59% | 70 Neutral | |
| AbbVie | 0.89% | $4.98M | $409.15B | 17.96% | 66 Neutral | |
| Regeneron | 0.89% | $4.95M | $84.90B | 18.11% | 78 Outperform | |
| Micron | 0.89% | $4.94M | $463.33B | 285.48% | 79 Outperform | |
| Merck & Company | 0.88% | $4.88M | $301.34B | 45.77% | 80 Outperform | |
| Bristol-Myers Squibb | 0.87% | $4.87M | $123.70B | 11.59% | 78 Outperform | |
| McKesson | 0.87% | $4.85M | $114.50B | 55.94% | 62 Neutral |
VFMF Technical Analysis
Positive
―
Price Trends
155.71
Positive
149.70
Positive
141.94
Positive
Market Momentum
2.21
Positive
61.39
Neutral
54.16
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For VFMF, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 159.82, equal to the 50-day MA of 155.71, and equal to the 200-day MA of 141.94, indicating a bullish trend. The MACD of 2.21 indicates Positive momentum. The RSI at 61.39 is Neutral, neither overbought nor oversold. The STOCH value of 54.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VFMF.
VFMF Peer Comparison
Comparison Results
Performance Comparison
VFMF
Vanguard U.S. Multifactor ETF
163.54
28.54
21.14%
SYLD
Cambria Shareholder Yield ETF
―
―
―
PLDR
Putnam Sustainable Leaders ETF
―
―
―
ABFL
Fcf Us Quality Etf
―
―
―
BGDV
Bahl & Gaynor Dividend ETF
―
―
―
XCHG
AB US Equity ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents